Monika Shirodkar, MD
Endocrinology, Diabetes & Metabolism · Philadelphia, PANPI 1497734602
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,750 of the $14,845 with a category attached, or 85.9%. AstraZeneca accounts for 90.7% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $10,477 and has fallen 94.9% since, to $534 in 2025.
Across 87 payments — averaging $170.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$13K
- Abbott$376
- Novo Nordisk$290
- Amgen$227
- Sanofi-aventis U.S. LLC$127
- Amarin Pharma, Inc.$70
- plus $287 from 9 others
Across 11 payments — averaging $2473.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amryt Pharma Holdings Ltd$10K
- Chiasma, Inc.$9K
- Novartis$8K
What the payments were for
- Speaking & faculty fees$12,75086%
- Travel & lodging$290%
- Food & beverage$2,06614%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 20 | $13,467 |
| Abbott | 19 | $376 |
| Novo Nordisk | 19 | $290 |
| Amgen | 9 | $227 |
| Sanofi-aventis U.S. LLC | 2 | $127 |
| Amarin Pharma, Inc. | 5 | $70 |
| Medtronic | 1 | $46 |
| Corcept Therapeutics | 2 | $40 |
| Pfizer | 2 | $39 |
| Amphastar Pharmaceuticals, Inc. | 2 | $37 |
| Radius Health, Inc. | 2 | $34 |
| Dexcom, Inc. | 1 | $29 |
| Amryt Pharma Holdings Ltd | 1 | $24 |
| Boehringer Ingelheim | 1 | $22 |
| Lilly USA, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$13,233
- SOLIQUA 100/33$102
How this compares
$14,845 in reported general payments places this provider in the 80th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 195 | $256,766 |
| JardianceEmpagliflozin | 121 | $134,739 |
| TrulicityDulaglutide | 60 | $88,496 |
| MounjaroTirzepatide | 48 | $70,218 |
| FarxigaDapagliflozin Propanediol | 36 | $60,555 |
| JanuviaSitagliptin Phosphate | 43 | $33,981 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $22,208 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $16,601 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 11 | $14,323 |
| TradjentaLinagliptin | 15 | $11,429 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 27 | $10,695 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 78 | $8,184 |
| Novolog FlexpenInsulin Aspart | 22 | $6,520 |
| Humalog Kwikpen U-100Insulin Lispro | 27 | $5,998 |
| VascepaIcosapent Ethyl | 12 | $4,709 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $290 | $258,815215 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Lyumjev | $16 | $161,929123 claims |
| Boehringer IngelheimJardiance, Tradjenta | $22 | $146,168136 claims |
| AstraZenecaFarxiga | $13,467 | $60,55536 claims |
| Sanofi-aventis U.S. LLCLantus | $127 | $1,35512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Philadelphia
- Serge JabbourPhiladelphia$1.2M
- Jane MayrinPhiladelphia$628K
- Intekhab AhmedPhiladelphia$528K
- Mitchell LazarPhiladelphia$358K
- Michael RickelsPhiladelphia$65K
- Amna KhanPhiladelphia$39K
- Janna PraterPhiladelphia$22K
- Anne CappolaPhiladelphia$17K
- Anastassia AmaroPhiladelphia$16K
- Vijay BahlPittsburgh$998K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.